<DOC>
	<DOCNO>NCT01959243</DOCNO>
	<brief_summary>To compare safety tolerability brimonidine tartrate ophthalmic solution 0.025 % versus vehicle population pediatric , adult , geriatric subject . At least 51 % subject 40 year age old .</brief_summary>
	<brief_title>Safety Brimonidine Tartrate Ophthalmic Solution Population Pediatric , Adult , Geriatric Subjects .</brief_title>
	<detailed_description />
	<mesh_term>Hyperemia</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Participants must least 5 year age Visit 1 either sex gender race ethnicity ; Have ocular health within normal limit , include calculate best correct ( necessary ) visual acuity 0.3 logMAR good eye , measure use Early Treatment Diabetic Retinopathy Study ( ETDRS ) chart . Have ocular/systemic health problem Use disallowed medication period indicate prior Visit 1 duration study .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Ocular redness</keyword>
</DOC>